DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Information Disclosure Statements Information Disclosure Statements (IDS) filed on 05/16/2024 and 12/ 0 9/2025 have been considered by the Examiner. A signed copy of the IDS is included with the present Office Action. Claims Status Applicant's election with traverse of a) sepsis and infectious disease conditions; agent which is a combination of tannic acid, Zn 2+ ions and gentamicin; and conditions being provided include inhibition of nucleic acid-sensed toll-like receptor (TLR) activation, (claim 1 a), and migration of microphage induced by activated microphage is reduced (claim 1 c); the patient is exposed to nucleic acid/ROS/LPS bacteria prior to administration of the agent i n the reply filed on 11/21/2025 is acknowledged. The traversal is on the ground(s) that additional species are inter related and fall under the general umbrella of claim 1. The additional details further narrow the scope of the claimed subject matter thus searching and considering the pending claims would not require significant expansion of efforts or increase in subject matter to be considered. This is not found persuasive because per MPEP 808.02, there are three reasons which can be provided for search burden, separate classification , separate status in the art even when they are classifiable together or a different field of search. Here, there would be a serious search burden because of the different field of search. For example, searching for sepsis with infectious disease requires different search queries /strings than a search for treatment of sepsis with a traumatic brain injury. In addition, sepsis related to the migration of macrophage induced by activated macrophage is unrelated to the mechanism of inhibiting TLR receptors. Applicants request that upon allowance of the single disclosed species, claims which require all the limitations of the allowed generic claim be considered for rejoinder . Examiner acknowledges that upon indication of allowable subject matter that species dependent from the allowable claim and require all the limitations of an allowable generic claim will be considered for rejoinder. The requirement is still deemed proper and is therefore made FINAL. Claims 8 , 10-12 and 18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 11/21/2025. Claims 1-7, 9, 13-17 and 19-20 are under current examination directed to the elected species of a combination of tannic acid, Zn 2+ ions and gentamicin; and conditions being provided include inhibition of nucleic acid-sensed toll-like receptor (TLR) activation, (claim 1 a), and migration of microphage induced by activated microphage is reduced (claim 1 c); the patient is exposed to nucleic acid/ROS/LPS bacteria prior to administration of the agent. Claim Rejections - 35 USC § 112(b) -indefinite The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 13 recites patient was exposed to a “nucleic acid/ROS/LPS/bacteria”. It is unclear if the claim requires exposure to all of a nucleic acid, ROS, LPS and bacteria , or if the exposure is to just one of these nucleic acid , ROS, LPS, or bacteria . For the purpose of examination , the claim will be interpreted in the alternative. Claim Rejections - 35 USC § 102 (a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale , or otherwise available to the public before the effective filing date of the claimed invention. Claim s 1-7, 9, 13-17 and 19-20 are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Liu et al. ( Targeting multiple mediators of sepsis using multifunctional tannic-acid-Zn2 + -gentamicin nanoparticles- published 11/3/2021 - see IDS filed on 12/09/25 ). Claim 1 recites: A method of targeting multiple mediators to treat sepsis which comprises administering to a patient in need thereof an agent comprising tannic acid, Zn 2 +, and gentamicin in an amount and under conditions to provide at least two of the following:(a) the inhibition of the nucleic acid-sensed toll-like receptor (TLR) activation is effected;(b) the inhibition on reactive oxygen species (ROS) induced DNA damage and cell death are effected;(c) the migration of microphage induced by activated microphage is reduced;(d) the generation of NO induced by lipopolysaccharides (LPS) is decreased; and(e) the immune response induced by bacteria is mitigated. Liu et al. teaches that multifunctional nanoparticles consisting of TA-Zn-Gen (tannic acid-zinc 2 + ions-gentamicin) improve sepsis treatment, see introduction . The nanoparticles have a net negative surface charge and exhibit high DNA binding activity, see page 4. The nanoparticles inhibit nucleic acid-induced TLR activation and activated macrophage induced macrophage migration. The TA-Zn-Gen nanoparticles inhibit cell free DNA induced TLR activation, inhibit activated macrophage induced macrophage recruitment, inhibition of ROS induced DNA damage and inhibit bacterial LPS induced NO production and inhibit bacteria induced inflammation, see introduction and inhibition of LPS-induced NO generation section . The reduction in NO mitigates inflammation response , and T A-Zn-Gen NPs reduce NO production in RAW 264.7 cells , see inhibition of LPS-induced nitric oxide generation section. The nanoparticles exhibit high DNA binding affinity due to electrostatic interactions, and increasing the gentamicin content displayed an increased DNA binding activity thus the nanoparticles bind nucleic acid depending on the concentration, see DNA binding affinity of TA-Zn-Gen NPs. Furthermore, the fact that the nanoparticles bind nucleic acid independent of structure, chemistry or sequence is characterizing a natural property of the nanoparticles. Products of identical chemical composition can not have mutually exclusive properties. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). TA-Zn-Gen NPs scavenge intracellular ROS and prevent ROS induced damage, wherein the blocking of ROS- related inflammatory macrophage singling is important for anti-sepsis activity. Serum of TA-Zn-Gen 3 NP treated mice show lowest TLR9 activation and reduced cf DNA level in serum thus indicating exposure of nucleic acid prior to administering the nanoparticles since the cfDNA was reduced after administration, see Anti-sepsis therapeutic activity of TA-Zn-Gen NPs in CLP-induced sepsis model section. TNF-alpha and IL-6 were detected in serum and peritoneal cavity of mice in the untreated group whereas the TA-Zn-Gen nanoparticles showed decreased TNF-alpha and IL-6 measurements thus inhibits TNF-alpha release , see Anti-sepsis therapeutic activity of TA-Zn-Gen NPs in CLP-induced sepsis model section of mice . Inhibition of TLR3 or TLR9 w a s measured using reporter cells involving poly (I:C) or C pG , see Inhibition of agonist-induced TLR3, TLR4, and TLR9 activation by NPs section. The TA-ZN-Gen NPs reduce inflammation as they have anti-inflammatory activity, see Anti-inflammatory effect of TA-Zn-Gen NPs in vitro section. The nucleic acid can be released form damaged cells. The TLR comprises TLR3 and TLR9 , the macrophage comprises RAW 264.7 , see anti-inflammatory effect of A-Zn- Gn NPs in vitro section. Macrophage activation is inhibited in a patient (in vivo) of mice, see Anti-sepsis therapeutic activity of TA-ZN-Gen NPs in CLP induced sepsis model section. The TA-Z n -Gen nanoparticles treat pathogenic bacteria such as Escherichia Coli , see antibacterial effect thus treat an infectious disease including bacterial infections caused by E. coli , see antibacterial effect section and inhibition of LPS-induced nitric oxide generation section. Accordingly , the teachings of Liu et al. which administers tannic acid, zinc 2+ and gentamicin nanoparticles anticipates the instantly claimed invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT SARAH ALAWADI whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-7678 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Monday-Friday 10:00am-6:30pm EST . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT David Blanchard can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-272-0827 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH ALAWADI/ Primary Examiner, Art Unit 1619